Navigation Links
GENUV Unveils Preclinical Advances in the Fight Against Alzheimer's Disease and ALS

GENUV, Inc., a clinical stage biotechnology company focused on innovative drug discovery for central nervous system disorders and developing advanced antibody therapies, presented three posters showing promising preclinical results for its new drug candidate for degenerative neurological conditions.

At the Keystone Virtual Symposium Neurodegenerative Disease: Genes, Mechanisms and Therapeutics, GENUV showed how its experimental drug SNR1611 (repurposing of approved drug trametinib) demonstrated positive neurogenesis and neuroprotective effects in mouse models of Alzheimer’s Disease and amyotrophic lateral sclerosis, or Lou Gehrig’s Disease. The results are an important validation of GENUV’s proprietary ATRIVIEW® platform, which screens for compounds that induce differentiation of neurons without neuronal cell death in disease-simulated conditions.

Among the key findings:

  • Trametinib protected motor neurons from degeneration by enhancing autophagy in a mouse model of ALS. The drug, approved by the U.S. Food and Drug Administration to treat certain cancers, was administered orally and resulted in increased survival rates, enhanced motor performance and improved grip strength.
  • In a mouse model of Alzheimer’s Disease, orally administered trametinib reduced beta amyloid plaque deposits and led to recovery of impaired neuronal structures and cognitive functions.
  • Also in a mouse model of Alzheimer’s, trametinib showed rescued cognitive deficits and the induction of endogenous neurogenesis in the cortex and hippocampus, primary sites for neuronal cell death in patients.

“GENUV is focused on discovering compounds that enhance neurogenesis and support neuroprotection,” said Sungho Han, Ph.D., founder and chief executive officer of GENUV. “We are encouraged by these preclinical findings, and believe ATRIVIEW® will play an important role in the discovery of new drug candidates that could potentially offer a breakthrough in the treatment of neurodegenerative diseases.”


GENUV Inc. is a leader in the discovery of drugs for central nervous system (CNS) disorders and advanced antibody therapies. The ATRIVIEW® drug screening platform uses cell phenotypic and biomarker analyses to discover compounds that induce the differentiation of neurons without triggering neuronal cell death. The company’s SHINE MOUSE® platform generates antibodies that have superior affinity and drugability. Based in Seoul, Korea, GENUV launched its first clinical trial in Korea in 2020. GENUV seeks to overcome the challenges in debilitating diseases using unique platform technology. Learn more at

Read the full story at

Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved

Related medicine technology :

1. Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms
2. Aribex Unveils New Color of NOMAD Pro 2
3. IBM Unveils Big Data, Cloud Enhancements Throughout Systems Portfolio
4. Roche unveils intelligent automation management solution at 2013 Clinical Lab Expo
5. Gulf Coast Spine Care Unveils New Treatments for Neck Pain
6. Frost & Sullivan Unveils Future Opportunities for the Tissue Diagnostics Market
7. Hospira Unveils New Quality Laboratory and Investments at Rocky Mount, N.C., Plant
8. Linwoods Superfoods Unveils Dynamic, Enhanced Website
9. Philips unveils breakthrough imaging innovations at RSNA 2013
10. Orcasonix Unveils Innovative Ultrasound Technology Built on Cephasonics cQuest Family of Ultrasound Systems
11. e-novex Unveils edc2go, High-Quality and Cost-Containing EDC
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):